Results 181 to 190 of about 6,896,550 (362)

Data‐driven discovery of gene expression markers distinguishing pediatric acute lymphoblastic leukemia subtypes

Molecular Oncology, EarlyView.
This study investigates gene expression differences between two major pediatric acute lymphoblastic leukemia (ALL) subtypes, B‐cell precursor ALL, and T‐cell ALL, using a data‐driven approach consisting of biostatistics and machine learning methods. Following analysis of a discovery dataset, we find a set of 14 expression markers differentiating the ...
Mona Nourbakhsh, Nikola Tom, Anna Schrøder Lassen, Helene Brasch Lind Petersen, Ulrik Kristoffer Stoltze, Karin Wadt, Kjeld Schmiegelow, Matteo Tiberti, Elena Papaleo   +8 more
wiley   +1 more source

Immune and Growth Factor Signaling Pathways Are Associated with Pathologic Complete Response to an Anti-Type I Insulin-like Growth Factor Receptor Regimen in Patients with Breast Cancer. [PDF]

Clin Cancer Res
Petricoin EF, Wolf DM, Yau C, Wulfkuhle JD, Van't Veer L, Gallagher RI, Esserman LJ, Hirst GL, Brown-Swigart L, Yee D, I-SPY2 Trial Consortium.   +10 more
europepmc   +1 more source

International Outsourcing and Productivity Growth [PDF]

This study investigates the impact of international outsourcing to low? and high income countries on total factor productivity growth based on manufacturing industry data for 14 OECD countries from 1995 ? 2000.
Martin Falk, Yvonne Wolfmayr
core  

TRPM8 levels determine tumor vulnerability to channel agonists

Molecular Oncology, EarlyView.
TRPM8 is a Ca2+ permissive channel. Regardless of the amount of its transcript, high levels of TRPM8 protein mark different tumors, including prostate, breast, colorectal, and lung carcinomas. Targeting TRPM8 with channel agonists stimulates inward calcium currents followed by emptying of cytosolic Ca2+ stores in cancer cells.
Alessandro Alaimo, Francesco Giuseppe Carbone, Kristi Buzo, Nicole Annesi, Sacha Genovesi, Annalisa Lorenzato, Karen Widmann, Michela Libergoli, Elisa Marmocchi, Giovanni Bertalot, Alberto Brolese, Mauro Giulio Papotti, Luca Molinaro, Orazio Caffo, Mattia Barbareschi, Alberto Bardelli, Alessandro Romanel, Sabrina Arena, Andrea Lunardi   +18 more
wiley   +1 more source

Resistance of recurrent epidermal growth factor receptor-altered glioblastoma to anti-epidermal growth factor receptor targeted therapy with osimertinib. [PDF]

Oncologist
Villanacci F, Prost D, Pieri F, Boetto J, Zucchi V, Giusti A, Jacob J, Nichelli L, Cupini S, Allegrini G, Della Porta M, Santonocito OS, Touat M, Di Stefano AL.   +13 more
europepmc   +1 more source

LIPOIDS AS THE GROWTH-INHIBITING FACTOR IN SERUM [PDF]

, 1925
Lillian E. Baker, Alexis Carrel
openalex   +1 more source

Nerve growth factor (NGF) in the central nervous system [PDF]

, 1990
Aguayo, A., Bandtlow, Christine, Bjorklund, A., Hengerer, Bastian, Heumann, Rolf, Lindholm, Dan, Meyer, Michael, Ottoson, D., Spranger, Matthias, Thoenen, Hans   +9 more
core   +1 more source

The anticancer effect of the HDAC inhibitor belinostat is enhanced by inhibitors of Bcl‐xL or Mcl‐1 in ovarian cancer

Molecular Oncology, EarlyView.
The pan‐HDAC inhibitor belinostat increases the expression of the pro‐apoptotic proteins Bim, Puma, and Noxa and induces apoptosis in ovarian cancer cell lines and patient‐derived tumor organoids when used at high concentrations. Moreover, inhibiting the anti‐apoptotic proteins Bcl‐xL or Mcl‐1 sensitizes these preclinical models to the cytotoxic effect
Cécilia Thomine, Sterenn Guillemot, Louis‐Bastien Weiswald, Romane Florent, Edwige Abeilard, Florence Giffard, Emilie Brotin, Mélanie Briand, Enora Dolivet, Laurent Poulain, Marie Villedieu   +10 more
wiley   +1 more source

Targeting nerve growth factor: an Achilles' heel for tumors? [PDF]

J Immunother Cancer
Repasky E, Mohammadpour H.
europepmc   +1 more source

Effectiveness of Unknown Growth Factors, Antibiotic, and Animal Fat in Turkey Poult Rations [PDF]

, 1958
P.E. Waibel
openalex   +1 more source